MedTrace Logo

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

NCT05814354 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2023-07-20

No results posted yet for this study

Summary

The aim of this study was to evaluate whether the progression-free survival of SHR-A1811 was superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer. To evaluate whether SHR-A1811 is superior to investigator-selected chemotherapy in patients with HER2-low recurrent/metastatic breast cancer.

Conditions

Interventions

DRUG

SHR-A1811

SHR-A1811 is a lyophilized powder for injection intravenously. Administered according to label, as one option for Physician's Choice.

DRUG

Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization).

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2025-01-30
Completion
2026-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05814354 on ClinicalTrials.gov